A prostate biopsy remains the gold standard to definitively diagnose prostate cancer. Traditionally, urologists have relied on systematic, transrectal ultrasound (TRUS)-guided biopsies, in which multiple cores (often 12 or more) are collected from various regions of the prostate. While widely used, this method samples tissue more or less blindly and can miss clinically significant tumors or over-detect insignificant ones.
Advantages of Ultrasound‑Guided Biopsies
Ultrasound-guided approaches offer distinct benefits. A classic TRUS biopsy allows real-time visualization of prostate anatomy during needle insertion, which increases sensitivity compared to non-imaging methods. A review of TRUS techniques showed that targeted ultrasound (including color Doppler or contrast-enhanced techniques) improves sensitivity over purely systematic sampling.
Moreover, ultrasound-guided biopsies are relatively quick, minimally invasive, and more widely accessible than MRI-based methods. In many clinical settings, TRUS remains the primary approach because of these practical advantages.
The Rise of Fusion-Guided Targeted Biopsy
To improve the precision of prostate biopsies, MRI/ultrasound fusion-guided biopsy has emerged as a powerful tool. Multiparametric MRI (mpMRI) helps identify suspicious lesions that may not be obvious on ultrasound. These MRI images are then co-registered (fused) with real-time ultrasound during the biopsy, allowing clinicians to sample targeted areas more precisely.
A landmark study showed that fusion-guided biopsies detect significantly more high-risk prostate cancers (Gleason ≥ 4+3) while reducing the detection of low-risk disease. By combining fusion-targeted cores with systematic sampling, clinicians can maximise detection of clinically significant cancers while minimising unnecessary overdiagnosis.
Reducing Complications: Transperineal vs Transrectal Approaches
Biopsy route also matters. While many TRUS biopsies are performed through the rectum, transperineal (TP) approaches are gaining traction because they carry a lower risk of infection, such as sepsis. A recent study reported that switching from TRUS to TP ultrasound-guided prostate biopsy markedly reduced post-procedural sepsis. In addition, meta-analyses suggest that TP and TR approaches have comparable cancer detection rates, but TP biopsies tend to have fewer rectal bleeding and urinary retention complications.
The Diagnostic Impact: Why Misses Matter
Missing a clinically significant cancer can have serious consequences. Systematic biopsy alone may under-detect aggressive cancer, while over-sampling can lead to overdiagnosis of indolent disease. Research shows that fusion-guided biopsy not only improves the detection of significant tumors, but also leads to upgrading the Gleason score in some patients compared to systematic biopsy alone. This precision is critical in guiding treatment decisions, whether active surveillance, focal therapy, or more aggressive interventions.
More accurate targeting can mean fewer needles, fewer unnecessary samples, and potentially lower complication risk. Patients benefit not just from better diagnostic yield, but also a more comfortable and safer biopsy experience. Additionally, the ability to tilt needle insertion angles and avoid “blind spots” (e.g. near the pubic bone) further enhances the safety and effectiveness of modern systems.
Introducing the UroMaster® Adventure: Next‑Gen Fusion Biopsy Technology
UromedTech’s UroMaster® Adventure is a state-of-the-art biopsy system designed to maximize precision and streamline workflow. It integrates real-time ultrasound imaging, MRI–US fusion, and a robotic transperineal guidance system, all in one compact platform. Its features include:
- Auto-segmentation and auto-registration for fast and accurate MRI-ultrasound fusion
- A robotic needle guide with adjustable insertion angle (± 30°) to avoid anatomical obstacles like the pubic bone
- An all-in-one workstation combining imaging, fusion software, and robotic control to save space and simplify procedures
By combining real-time imaging, AI-powered fusion workflow, and robotic precision, UroMaster® Adventure addresses many of the limitations of traditional biopsy methods. It helps urologists detect cancer more reliably, reduces sampling error, and can potentially lower the rates of repeat biopsies. Ultimately, the system empowers clinicians to make more informed, confident decisions, while improving safety and comfort for patients.
If you wish to learn more about the UromedTech UroMaster® Adventure, visit our page now: https://bmec.asia/uromedtech
More Information
- (n.d.). Our Technology – UroMaster® Adventure. Retrieved from https://www.uromedtech.com/our-technology
- Siddiqui, M. M., Rais-Bahrami, S., Truong, H., et al. (2013). Magnetic Resonance Imaging/Ultrasound–Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12‑core Transrectal Ultrasound Biopsy. European Urology, 64, S0302283813005988.
- Power, J. W., de la Rosette, J. J., & Somani, B. K. (2022). Change from transrectal to transperineal ultrasound-guided prostate biopsy under local anaesthetic eliminates sepsis as a complication. Urology, S0195670122000974.
- Dorfinger, J., et al. (2022). MRI/ultrasound fusion-guided prostate biopsy can detect more cases of prostate cancer than systematic biopsy alone, especially clinically significant cancer: a retrospective analysis of 524 cases. Journal of Urology.
UromedTech / BMEC Pte Ltd